- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07314164
Estudo de Cabozantinib em Participantes com Tumores Neuroendócrinos que já Receberam Tratamento Prévio (CaboLife)
CaboLife: Um Estudo Prospectivo Não-Intervencionista sobre a Eficácia e Segurança do Cabozantinibe em Contexto de Vida Real para Doentes com Tumor Neuroendócrino Previamente Tratados
This study will assess how well cabozantinib works and how safe it is in adults with a type of cancer called neuroendocrine tumors (NETs).
These tumors can appear in all parts of the body. All participants in this study have already received at least one treatment that affects the whole body to help manage their cancer, but their disease has continued to grow.
The study will take place in regular hospitals and clinics in Germany and Austria.
It will follow about 150 participants who are taking cabozantinib as part of their usual care. Doctors will collect information from routine medical visits, tests, and scans to see how the cancer responds to treatment and how long participants stay on cabozantinib. They will also look at side effects and how the treatment affects participants' quality of life.
This is an observational study, which means that no extra tests or procedures will be done beyond what is normally used to care for participants with this condition.
Visão geral do estudo
Status
Condições
Tipo de estudo
Inscrição (Estimado)
Contactos e Locais
Contato de estudo
- Nome: Ipsen Clinical Study Enquiries
- Número de telefone: See e mail
- E-mail: clinical.trials@ipsen.com
Locais de estudo
-
-
-
Aschaffenburg, Alemanha
- Recrutamento
- MVZ am Klinikum Aschaffenburg
-
Berlin, Alemanha
- Recrutamento
- Evangelische Lungenklinik Berlin
-
Berlin, Alemanha
- Recrutamento
- DRK Kliniken Berlin
-
Berlin, Alemanha
- Recrutamento
- Charité - Universitaetsmedizin Berlin
-
Bonn, Alemanha
- Ainda não está recrutando
- Johanniter-Kliniken Bonn
-
Bremen, Alemanha
- Recrutamento
- Krankenhaus St. Joseph-Stift Bremen GmbH
-
Chemnitz, Alemanha
- Ainda não está recrutando
- Klinikum Chemnitz
-
Cologne, Alemanha
- Recrutamento
- pioh Studien und Mangement GbR
-
Cologne, Alemanha
- Recrutamento
- MVZ fuer Haematologie und Onkologie Koeln am Sachsenring
-
Dresden, Alemanha
- Recrutamento
- Gemeinschaftspraxis Haematologie - Onkologie
-
Dresden, Alemanha
- Recrutamento
- Technische Univiersitaet (TU) Dresden
-
Erlangen, Alemanha
- Recrutamento
- Universitaetsklinikum Erlangen
-
Essen, Alemanha
- Recrutamento
- Universitaetsklinikum Essen
-
Frankfurt, Alemanha
- Ainda não está recrutando
- Krankenhaus Nordwest
-
Frankfurt am Main, Alemanha
- Ainda não está recrutando
- Uniklinikum Frankfurt
-
Freiburg im Breisgau, Alemanha
- Recrutamento
- Universitaetsklinikum Freiburg
-
Giesen, Alemanha
- Ainda não está recrutando
- Universitaetsklinikum Giessen-Marburg
-
Goettigen, Alemanha
- Recrutamento
- Universitaetsmedizin Goettingen
-
Hamburg, Alemanha
- Recrutamento
- Universitaetsklinikum Hamburg-Eppendorf
-
Hamburg, Alemanha
- Ainda não está recrutando
- Asklepios Kliniken Hamburg
-
Heidelberg, Alemanha
- Ainda não está recrutando
- Universitaetsklinikum Heidelberg
-
Kiel, Alemanha
- Ainda não está recrutando
- UKSH Kiel
-
Leer, Alemanha
- Ainda não está recrutando
- Studienzentrum UnterEms
-
Leipzig, Alemanha
- Ainda não está recrutando
- MVZ Leipzig Mitte, MVZ Delitzsch
-
Leipzig, Alemanha
- Ainda não está recrutando
- Universiteatsmedizin Leipzig
-
Ludwigsburg, Alemanha
- Recrutamento
- RKH Kliniken Ludwigsburg-Bietigheim gGmbH
-
Lübeck, Alemanha
- Ainda não está recrutando
- UKSH Luebeck
-
Mainz, Alemanha
- Ainda não está recrutando
- Universitaetsmedizin Mainz
-
Marburg, Alemanha
- Recrutamento
- Philipps-Universitaet Marburg
-
Minden, Alemanha
- Recrutamento
- Johannes Wesling Klinikum Minden der Muehlenkreiskliniken AoeR
-
Mülheim, Alemanha
- Recrutamento
- MVZ Muelheim an der Ruhr GmbH
-
München, Alemanha
- Ainda não está recrutando
- TUM Klinikum Muenchen
-
Münster, Alemanha
- Ainda não está recrutando
- Universitaetsklinikum Muenster
-
Osnabrück, Alemanha
- Ainda não está recrutando
- MVZ Onkologie Klinikum Osnabrueck GmbH
-
Saarbrücken, Alemanha
- Ainda não está recrutando
- Universitaestklinikum Saarbruecken
-
Tübingen, Alemanha
- Recrutamento
- Universitätsklinikum Tuebingen
-
Westerstede, Alemanha
- Recrutamento
- Medizinische Studiengesellschaft Nord-West
-
Würzburg, Alemanha
- Recrutamento
- Universitaetsklinikum Wuerzburg
-
-
-
-
-
Graz, Áustria
- Recrutamento
- Medizinische Universitaet Graz
-
Linz, Áustria
- Ainda não está recrutando
- Kepler Universitaetsklinikum GmbH Linz
-
Vienna, Áustria
- Recrutamento
- Medizinische Universität Wien
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
150 adult participants in Austria and Germany who are prescribed cabozantinib tablets for unresectable or metastatic, well differentiated extra-pancreatic (epNET) and pancreatic (pNET) neuroendocrine tumours who have progressed following at least one prior systemic therapy other than somatostatin analogues prior to entry into the study will be included.
Descrição
Inclusion Criteria:
Participants can join the study if they meet all of the following conditions:
- Are 18 years or older and able to give informed consent.
- Have a physician-initiated decision to start treatment with cabozantinib for neuroendocrine tumors (NETs), made before joining the study.
- Have unresectable or metastatic, well-differentiated pancreatic (pNET) or extra-pancreatic neuroendocrine tumors (epNET).
- Have already received at least one prior systemic therapy, other than somatostatin analogues.
- Have signed a written informed consent form.
Exclusion Criteria:
Participants cannot join the study if:
- They are currently participating in an interventional clinical trial, or have done so within the last 3 months before joining this study.
- They have a contraindication to cabozantinib treatment, based on the product's official prescribing information.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Modelos de observação: COHORT
- Perspectivas de Tempo: PROSPECTIVE
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Disease Control Rate (DCR)
Prazo: At 6 Months
|
Proportion of participants who achieve complete response, partial response, or stable disease within 6 months of cabozantinib treatment, based on radiographic assessments performed as part of routine care. |
At 6 Months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Objective Response Rate (ORR)
Prazo: Up to 18 Months
|
Proportion of participants who achieve complete or partial response based on radiographic assessments. |
Up to 18 Months
|
|
Change from baseline in global and subscale scores of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC QLQ-C30)
Prazo: Baseline and Every 3 Months up to 18 Months
|
A validated 30-item questionnaire designed to assess the general health-related quality of life of cancer patients. It includes: 5 functional scales (physical, role, emotional, cognitive, social), 3 symptom scales (fatigue, nausea/vomiting, pain) a global health status/QoL scale and several single items (e.g., dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties). |
Baseline and Every 3 Months up to 18 Months
|
|
Change from baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Gastrointestinal Neuroendocrine Tumors Module (EORTC QLQ-GINET21)
Prazo: Baseline and Every 3 Months up to 18 Months
|
A 21-item module developed to supplement the QLQ-C30 for patients with gastrointestinal neuroendocrine tumors (GI-NETs). It includes 5 scales (Endocrine symptoms, Gastrointestinal symptoms, Treatment-related side effects, Social functioning, Disease-related worries) and 5 single items (weight loss, weight gain, muscle and/or bone pain, information, sexual functioning). |
Baseline and Every 3 Months up to 18 Months
|
|
Percentage of participants experiencing Adverse Events (AEs), non-serious, drug-related, or serious Adverse Events (SAEs)
Prazo: Up to 18 Months
|
An Adverse event (AE) is any untoward medical occurrence, temporally associated with the use of study intervention, whether or not related to the study intervention. |
Up to 18 Months
|
|
Percentage of participants with any dose modification due to AEs.
Prazo: Up to 18 months
|
Percentage of participants who experienced at least one dose reduction, interruption, or discontinuation due to adverse events during the study period. |
Up to 18 months
|
|
Duration of treatment (DoT)
Prazo: Up to 18 Months
|
Time from first dose to last dose of cabozantinib. |
Up to 18 Months
|
|
Percentage of participants switching to a new line of therapy
Prazo: Up to 18 Months
|
Percentage of participants who initiated a new line of therapy during the study period. The type of therapy received after switch will be reported descriptively and is not considered a formal outcome measure. |
Up to 18 Months
|
|
Disease control rate after switch to next line of therapy
Prazo: 3 Months After Therapy Switch
|
Proportion of participants achieving complete response, partial response, or stable disease within 3 months after switching to a new therapy, based on radiographic assessment performed as part of routine care. |
3 Months After Therapy Switch
|
|
Chromogranin A Levels
Prazo: Baseline and Every 3 Months up to 18 Months
|
Chromogranin A blood levels measured during routine care. |
Baseline and Every 3 Months up to 18 Months
|
|
Neuron-Specific Enolase blood levels.
Prazo: Baseline and Every 3 Months up to 18 Months
|
Neuron-Specific Enolase blood levels measured during routine care. |
Baseline and Every 3 Months up to 18 Months
|
|
Time to next treatment
Prazo: Up to 18 Months
|
Time from first dose of cabozantinib to initiation of subsequent therapy. |
Up to 18 Months
|
|
Progression-Free Survival (PFS)
Prazo: Up to 18 Months
|
Time from first dose of cabozantinib to disease progression or death from any cause. |
Up to 18 Months
|
|
Progression-Free Survival Rate at 12 and 18 Months
Prazo: At 12 and 18 Months
|
Number of participants without disease progression or death. |
At 12 and 18 Months
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Diretor de estudo: Ipsen Medical Director, Ipsen
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- CLIN-60000-467
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications.
Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.
Prazo de Compartilhamento de IPD
Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the United States (US) and/or Europe (EU).
Critérios de acesso de compartilhamento IPD
Further details on Ipsen's sharing criteria and process for sharing are available here (https://www.ipsen.com/science/clinical-trials/clinical-data-transparency/).
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .